
Amanda Piquet, MD, FAAN, discussed phase 2 data from a trial evaluating the CAR-T therapy mivocabtagene autoleucel for the treatment of stiff person syndrome.
The director of the autoimmune neurology program at the University of Colorado

Amanda Piquet, MD, FAAN, discussed phase 2 data from a trial evaluating the CAR-T therapy mivocabtagene autoleucel for the treatment of stiff person syndrome.

The director of the autoimmune neurology program at the University of Colorado discussed data from a phase 2 single-arm registrational trial evaluating Kyverna Therapeutics’ CAR-T.